Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

EHAVE, Inc. (EHVVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0065+0.0002 (+3.17%)
At close: 11:59AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0063
Open0.0067
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0063 - 0.0068
52 Week Range0.0031 - 0.0275
Volume28,550
Avg. Volume306,128
Market Cap654,082
Beta (5Y Monthly)2.88
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022

    MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will accept delivery of its KetaDASH Mobile Unit in Miami Beach Florida on June 10, 2022. The KetaDASH Mobile Unit is a custom high-end medical van utilizing KetaDASH’s software platform. By bringing exclusive Ketamine IV treatments directly to the patient, KetaDASH will empower doctors and patients with real-time he

  • GlobeNewswire

    Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

    AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med

  • GlobeNewswire

    Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ

    Ehave owns approximately 9,793,754 shares of Mycotopia Therapies valued at more than $24 million, as of Friday’s closing price; Plans partial distribution to shareholdersMIAMI, May 23, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today that its Mycotopia Therapies (OTC: TPIA) subsidiary has signed a definitive agreement to complete a triangular merger with Ei.Ventures, an early-stage tech company empoweri

Advertisement
Advertisement